SGLT2 Inhibitors: Now The Bad News
Sodium-glucose cotransporter-2 inhibitors are approved as adjunctive therapy for the treatment of patients with type 2 diabetes. This drug class has been also used off-label to improve glycemic control in patients with type 1 diabetes.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.